A highly targeted treatment that relies on the patient's own stem cells improves outcomes for children with brain tumors called medulloblastomas, U.S. researchers report. Children with high-risk medulloblastoma have a 30 percent to 40 percent chance of surviving to five years, and chemotherapy usually lasts for about 12 months. However, "not only can we now cure about 70 percent of children with high-risk medulloblastoma, we can also cure more than 80 percent of those with standard-risk disease with a shorter, and therefore more convenient, chemotherapy approach," lead researcher Dr. Amar Gajjar, from St Jude's Children's Research Hospital in Memphis, said...